Mathieu LN, Larkins E, Akinboro O, Roy P, et al. FDA Approval Summary: Capmatinib and Tepotinib for the Treatment of Metastatic NSCLC Harboring MET Exon 14 Skipping Mutations or Alterations. Clin Cancer Res 2022;28:249-254.
PMID: 34344795